Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000936 · ClinicalTrials.gov registry record · Phase 3
A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 3
- Development phase
- 292
- Enrollment target
NCT00000936 is a Phase 3 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 292 participants.
The verdict
NCT00000936, a Phase 3 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 292 participants
- Enrollment target
Study Summary
Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches. Two medications in this study are currently used in children, but there is no information regarding which drug is safer or more effective. Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for an improved post-transplant treatment, such as the induction therapy used in this study.
Interventions
- DRUG Oral Cyclosporine
- DRUG hOKT3
- DRUG IV Cyclosporine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 1999-11 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000936
The ClinicalTrials.gov registry entry for NCT00000936 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oral Cyclosporine is the first listed.
NCT00000936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000936 about?
NCT00000936 is a clinical study titled "A Study To Test An Anti-Rejection Therapy After Kidney Transplantation". Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches. Two medications in this study are currently used in children, but there is no information reg...
What is the current status of trial NCT00000936?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 1999-11. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00000936?
The interventions under investigation include: Oral Cyclosporine (DRUG), hOKT3 (DRUG), IV Cyclosporine (DRUG).
Who is sponsoring clinical trial NCT00000936?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.